Review of recent advances in label-free quantification in cancer proteomics

In recent years, proteomics research has become a popular method for characterizing the functional proteins driving the transformation of malignancy, tracing the large-scale protein alterations induced by anti-cancer drug, as well as discovering the innovative targets and first-in-class drugs for oncologic disorders. Proteomics became popular due to its ability to provide quantitative and dynamic information on tumor genesis and development by directly profiling protein expression. Label-free Quantification (LFQ) is an important method for quantifying protein expression in cancer proteomics. However, the main challenge in using this method for discovering anti-cancer targets and drugs is the low precision, poor reproducibility, and inaccuracy of the LFQ of proteomics data.

This paper presents a review of the recent advances and the computational development of LFQ in cancer proteomics. PubMed and Web of Science databases were searched for label-free quantification approaches, cancer proteomics, and computational advances. A number of experiments including popular acquisition techniques and state-of-the-art quantification tools are critically analyzed and discussed. Following this, the processing approaches which included transformation, normalization, filtering, and imputation were discussed and their impacts on improving LFQ performance of cancer proteomics were evaluated.

The authors also discuss the future direction for enhancing the computation-based quantification technique for cancer proteomics. The dramatic increase in the use of LFQ approaches in cancer proteomics can lead to the enhancement of quantification strategies for studying cancer proteomics in the future once its limitations are accounted for.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
New blood test offers more precise diagnostics of ovarian cancer